Clinical Trial Update: Safety and Efficacy of Azithromycin to Treat Cutaneous Leishmaniasis [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update indicates the Phase 2/Phase 3 study evaluating azithromycin for treating Cutaneous Leishmaniasis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Leishmaniasis

Drugs mentioned

• Azithromycin (azithromycin)

Snippet

Sponsor: Ana Rabello | Conditions: Cutaneous Leishmaniasis | Phase 2, Phase 3 | Status: TERMINATED